Active surveillance in prostate cancer: Patient selection and triggers for intervention

Current Opinion in Urology

Volumn 22, Issue 3, 2012, Pages 210-215

  Lees, Kathryn ^a   Durve, Meeta ^a   Parker, Chris ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

active surveillance; intervention triggers; multiparametric MRI; patient selection; prostate biopsy, prostate cancer; prostate specific antigen kinetics

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER SURGERY; CLINICAL PRACTICE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HEALTH STATUS; HISTOLOGY; HUMAN; LIFE EXPECTANCY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; TUMOR LOCALIZATION; TUMOR VOLUME;

DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PATIENT SELECTION; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNNECESSARY PROCEDURES; WATCHFUL WAITING;

EID: 84859630507     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328351dc47     Document Type: Review

References (37)

1. Soloway MS, Soloway CT, Eldefrawy A, et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010; 58:831-835. This is a study from the University of Miami group active surveillance cohort. Two hundred and thirty patients were followed for a mean of 44 months. Fourteen percent have required definitive treatment. There have not been any cancer deaths. PSADT and clinical stage did not predict the need for treatment.
2. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. JCO 2011; 29:2185-2190. This is an update from the Johns Hopkins group of their 769 patient cohort of low-risk patients on active surveillance. There has been prospective follow-up for a median of 2.7 years (0.01-15) with 6 monthly PSA and annual repeat biopsies. Progression was classified by biopsy criteria alone. Eighty one, 59 and 41% of men required intervention at 2, 5 and 10 years, respectively. Overall, 33.2% required intervention. There have been no prostate cancer deaths.
3. Stattin P, Holmberg E, Johansson J, et al. Outcomes in localised prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102:950-958.
4. Epstein JL, Walsh P, Carmichael M, et al. Pathologic and clinical findings to predict tumour extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:368-374. (Pubitemid 24037911)
5. Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Onc 2011; 29:2795-2800. These are the results reported from the University of California, San Francisco Group of 377 men in their cohort. Active surveillance patients had 3 monthly PSA tests and repeat biopsies at UCSF every 12-24 months. They compared serial biopsies and found 34% of men had an upgrade in their Gleason score. Eighty-one percent of those upgraded had so on their second biopsy. Of those who had mapping biopsies at diagnosis and a future upgrade, 37% did so in a previously uninvolved site.
6. Klotz L, Zhang L, Lam A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. JCO 2010; 28:126-131. These are results of a prospective active surveillance program for Toronto. They have followed 450 low-risk patients for a median of 6.8 years (1-13). Patients had a 3 monthly PSA for 2 years then 6 monthly while stable. Repeat biopsy was performed after 6-12 months and then every 3-4 years. Criteria for intervention were classified as a PSADT less than 3 years (2 years for the initial 4 years of the program), Gleason 4+3 or more or clinical progression. Their 10-year prostate cancer acturial survival is 97.2% and an overall survival 78.6%. Hazard ratio for nonprostate cancer-to-prostate cancer deaths mortality was 33.3 (95% CI 8.2-136) in 70-year olds or older and 8.76 (95% CI 2.65-28.9) in younger than 70-year-olds.
7. van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localized prostate cancer managed by active surveillance. Euro Urol 2008; 54:1297-1305.
8. Cooperberg MR, Cowan JE, Hilton JF, et al. Outcomes of active surveillance for men with intermediate risk prostate cancer. J Clin Oncol 2011; 29:228-234.
9. Ploussard G, Xylinas E, Salomon L, et al. The role of biopsy core number in selecting patients for active surveillance. Eur Urol 2009; 56:891-898.
10. Barqawi A, Rove K, Gholizadeh S, et al. Role of 3-dimensional mapping biopsies in decision making for treatment of apparent early stage prostate cancer. J Urol 2011; 186:80-85.
11. Ayres BE, Montgomery BS, Barber NJ. The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. BJU Int 2011. [E-pub ahead of print] Onehundred and one cohort of patients entered on to an active surveillance program with transrectal biopsies who were restaged with template prostate biopsies. Thirty-four percent were found to have more significant disease on Gleason score or tumour volume. Of the men upstaged, 44% had disease predominantly in the anterior gland.
12. Kotb AF, Tanguay S, Luz MA. Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance. Prostate Cancer and Prostatic Dis 2011; 14:53-57.
13. San Francisco I, Werner L, Regan MJ, et al. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011; 185:471-476.
14. Tseng K, Landis P, Epstein J, et al. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010; 183:1779-1785.
15. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007; 178:2359-2364.
16. van den Bergh RC, Vasarainen H, van der Poel H, et al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int 2010; 105:956-962.
17. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008; 112:2664-2670. (Pubitemid 351969209)
18. Donovan J, Hamdy F, Neal D, et al., ProtecT Study Group. Prostate Testing For Cancer And Treatment (ProtecT) Feasibility Study. Health Technol Assess 2003; 7:1-8.
19. Fall K, Garmo H, Andrén O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. JNCI 2007; 99:526-532. (Pubitemid 47073555)
20. Daskivich TG, Regan M., Oh WK. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 2006; 176:1927-1937. (Pubitemid 44633182)
21. Choo R, DeBoer G, Klotz L, et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50:615-620. (Pubitemid 32519594)
22. Stephenson AJ, Aprikian A, Souhami L, et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002; 59:652.
23. D'Amico AV, Chen M, Roehl K, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351:125.
24. D'Amico AV, Renshaw A, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294:440-447. (Pubitemid 41124176)
25. Sengupta S, Myers R, Slezak J, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174:2191-2196. (Pubitemid 41611772)
26. Ng MK, Van As N, Thomas K, et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU int 2009; 103:872-876.
27. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Onc 2010; 28:2810-2816.
28. Loblaw A, Zhang L, Lam A, et al. Comparing PSA triggers for intervention in men with stable prostate cancer on active surveillance. J Urol 2010; 184:1942-1946.
29. Van As NG, de Souza NM, Riches SF, et al. A study of diffusion weighted magnetic resonance imaging in men with untreated localized prostate cancer on active surveillance. Eur Urol 2009; 56:981-987.
30. Morgan V, Riches SF, Thomas K, et al. Diffusion weighted MRI for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 2011; 84:31-37.
31. Giles S, Morgan V, Riches S, et al. Apparent diffusion coefficient as a predictive biomarker for prostate cancer progression. Am J Roentgenol 2011; 196:586-591.
32. Fradet V, Kurhanewicz J, Cowan JE, et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology Jul 2010; 256:176-183.
33. Englelbrecht M, Puech P, Colin P. Mulitmodal magnetic resonance imaging for prostate cancer. J Endourol 2010; 24:677-684.
34. Ploussard G, Xylinas E, Durand X, et al. Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on saturation biopsy scheme. BJU Int 2011; 108:513-517.
35. Tousain J, Loeb S, Kettermann A, et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010; 183:534-538.
36. Makarov D, Isharwal S, Sokoll L, et al. ProPSA measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009; 15:7316-7321.
37. Isharwal S, Makarov D, Sokoll L, et al. Pro PSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011; 77:763; e1-6.